Cargando…
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452075/ https://www.ncbi.nlm.nih.gov/pubmed/37626687 http://dx.doi.org/10.3390/biomedicines11082191 |
_version_ | 1785095577423314944 |
---|---|
author | Potestio, Luca Battista, Teresa Cacciapuoti, Sara Ruggiero, Angelo Martora, Fabrizio Fornaro, Luigi Camela, Elisa Megna, Matteo |
author_facet | Potestio, Luca Battista, Teresa Cacciapuoti, Sara Ruggiero, Angelo Martora, Fabrizio Fornaro, Luigi Camela, Elisa Megna, Matteo |
author_sort | Potestio, Luca |
collection | PubMed |
description | COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo psoriasis or the exacerbation of psoriasis following COVID-19 vaccination. However, data on the possible pathogenetic mechanisms as well as comprehensive manuscripts on the topic are scant. Thus, the aim of our manuscript was to perform a review of the current literature on post-COVID-19 vaccination exacerbations and new-onset psoriasis in order to offer a wide perspective on this area and to point out possible pathogenetic mechanisms. Research on the current literature was performed following PRISMA guidelines. In total, 49 studies involving 134 patients developing new-onset psoriasis (n = 27, 20.1%) or psoriasis exacerbation (n = 107, 79.9%) were collected. Although cases of de novo psoriasis or a worsening of psoriasis have been reported following vaccination, all of the cases have been successfully treated while overall benefit–risk profile of COVID-19 vaccination does not justify vaccine hesitancy due to the risk of psoriasis being developed or worsening. Certainly, further studies are needed to identify possible pathogenetic mechanisms in order to identify “at-risk” patients. Finally, vaccination should not be discouraged. |
format | Online Article Text |
id | pubmed-10452075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104520752023-08-26 New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge Potestio, Luca Battista, Teresa Cacciapuoti, Sara Ruggiero, Angelo Martora, Fabrizio Fornaro, Luigi Camela, Elisa Megna, Matteo Biomedicines Review COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo psoriasis or the exacerbation of psoriasis following COVID-19 vaccination. However, data on the possible pathogenetic mechanisms as well as comprehensive manuscripts on the topic are scant. Thus, the aim of our manuscript was to perform a review of the current literature on post-COVID-19 vaccination exacerbations and new-onset psoriasis in order to offer a wide perspective on this area and to point out possible pathogenetic mechanisms. Research on the current literature was performed following PRISMA guidelines. In total, 49 studies involving 134 patients developing new-onset psoriasis (n = 27, 20.1%) or psoriasis exacerbation (n = 107, 79.9%) were collected. Although cases of de novo psoriasis or a worsening of psoriasis have been reported following vaccination, all of the cases have been successfully treated while overall benefit–risk profile of COVID-19 vaccination does not justify vaccine hesitancy due to the risk of psoriasis being developed or worsening. Certainly, further studies are needed to identify possible pathogenetic mechanisms in order to identify “at-risk” patients. Finally, vaccination should not be discouraged. MDPI 2023-08-03 /pmc/articles/PMC10452075/ /pubmed/37626687 http://dx.doi.org/10.3390/biomedicines11082191 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Potestio, Luca Battista, Teresa Cacciapuoti, Sara Ruggiero, Angelo Martora, Fabrizio Fornaro, Luigi Camela, Elisa Megna, Matteo New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title | New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title_full | New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title_fullStr | New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title_full_unstemmed | New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title_short | New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge |
title_sort | new onset and exacerbation of psoriasis following covid-19 vaccination: a review of the current knowledge |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452075/ https://www.ncbi.nlm.nih.gov/pubmed/37626687 http://dx.doi.org/10.3390/biomedicines11082191 |
work_keys_str_mv | AT potestioluca newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT battistateresa newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT cacciapuotisara newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT ruggieroangelo newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT martorafabrizio newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT fornaroluigi newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT camelaelisa newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge AT megnamatteo newonsetandexacerbationofpsoriasisfollowingcovid19vaccinationareviewofthecurrentknowledge |